RNA vaccines articles from across Nature Portfolio

Current RSV vaccines induce immunity with limited durability in pre-exposed populations. Here, the authors generated an RSV preF self-amplifying RNA vaccine and show that a single dose induces potent innate, cellular, and humoral immunity in RSV-infected in naïve and pre-exposed non-human primates.

Longitudinal sampling of human lymph nodes using fine-needle aspiration after influenza or SARS-CoV-2 vaccination reveals substantial durability and transcriptional reprogramming of follicular helper T cells over time.

The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), convened a virtual workshop on August 8-9^th, 2023 to explore potential synergies between HIV vaccine approaches that are designed to induce cellular or humoral immune responses. The goal of this workshop was to review data on leading vaccine candidates and to discuss the best strategies for combining these approaches to optimize immunity against HIV. Here, we summarize the findings reviewed at the workshop and discuss the knowledge gaps and priorities for future studies that will help accelerate the development of a preventive HIV vaccine.

In patients with resected, high-risk melanoma, the addition of a personalized mRNA-based neoantigen therapy to adjuvant pembrolizumab was more effective than pembrolizumab alone.

The use of T cell receptor signatures to track activated spike-specific T cell dynamics between recovery from SARS-CoV-2 infection and subsequent mRNA vaccination shows that vaccination effectively recruits pre-existing memory and new CD8⁺ T cell clonotypes.